DSM-Firmenich elected a new chair. DSM-Firmenich stock sits 0.91 percent below its high.

Published on 10/26/2026 at 10:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ridinger became chair on October 19, 2026. DSM-Firmenich stock costs EUR 108.85 on October 26, 2026 versus its EUR 109.85 high.

Board change and operating metrics

Richard Ridinger became chairman on October 19, 2026, after serving on the board since 2023.
Continuing operations generated EUR 4.664 billion in first-half 2026 revenue and EUR 900.00 million in adjusted EBITDA.
DSM-Firmenich stock trades at EUR 108.85 at 10:00 a.m. CEST at Lang & Schwarz on October 26, 2026.
The next scheduled sales update is November 4, 2026.

Fotorealistisches Duftlabor mit Wissenschaftlern und Destillationsanlagen — dsm-firmenich AG (ISIN CH1216478797) betreibt moderne Duftlabore mit Wissenschaftlern und Analysegeräten für Aromastoffe, Illustration mit AI erstellt.

DSM-Firmenich (ISIN CH1216478797) was trading at EUR 108.85 at Lang & Schwarz on October 26, 2026 at 10:00 a.m. CEST, 0.91 percent below its 52-week high of EUR 109.85. The latest company event was the election of Richard Ridinger as chairman at the October 19, 2026 Extraordinary General Meeting, according to dsm-firmenich.

Three milestones shape the story

The recent sequence began on July 30, 2026, when dsm-firmenich reported first-half continuing-operations revenue of EUR 4.664 billion and adjusted EBITDA of EUR 900.00 million, according to De Belegger. On October 1, 2026, the company completed a EUR 540.00 million share repurchase program, according to GlobeNewswire. On October 19, 2026, shareholders elected Ridinger chairman; he has served as an independent director since 2023, the company said.

What does the margin say?

The half-year figures point to a business that is converting growth into operating earnings. Comparable revenue growth was 5.00 percent in the first half of 2026 and 6.00 percent in the second quarter, while adjusted EBITDA represented 19.30 percent of first-half revenue and 19.50 percent in the second quarter, according to De Belegger. Management retained a full-year 2026 adjusted EBITDA margin target of 20.00 percent and a gross operating free cash flow target of 11.00 to 12.00 percent of revenue. For investors, the key test is whether the higher margin also produces stronger cash conversion.

Next date is November 4

The next scheduled company event is the third-quarter 2026 sales update on November 4, 2026, according to the financial calendar published by Ideal Investisseur. That release should show whether the 6.00 percent comparable growth rate from the second quarter carried into the second half.

Stock remains near its yearly high

The Lang & Schwarz quote places the stock 0.91 percent below its EUR 109.85 52-week high on October 26, 2026. The market capitalization was EUR 26.5 billion on the same date, while the reported 52-week range was EUR 55.22 to EUR 109.85.

DSM-Firmenich was trading at EUR 108.85 at Lang & Schwarz on October 26, 2026 at 10:00 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.